Business Context and Reporting Period
Company: Aldeyra Therapeutics, Inc. (ALDX)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: Aldeyra is a clinical-stage biotechnology company focused on discovering and developing therapies for immune-mediated diseases. Its primary late-stage product candidate is reproxalap for dry eye disease. The company has no approved products and relies on funding from equity sales, debt, and potential collaborations.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3,452,619) | $(9,929,501) |
| Loss Per Share (Basic & Diluted) | $(0.06) | $(0.17) |
| Research & Development Expenses | $2,409,575 | $7,423,324 |
| General & Administrative Expenses | $1,137,343 | $3,004,135 |
| Cash and Cash Equivalents (End of Period) | $65,002,305 | $50,350,617 |
| Net Cash Used in Operating Activities | $(5,110,089) | $(12,469,699) |
| Total Debt (Current Portion) | $15,300,000 | $15,249,632 |
| Total Stockholders' Equity | $42,156,792 | $63,598,577 |
Note: The company reported no revenue for the period. The "Current portion of debt" includes the principal balance of the Hercules Credit Facility plus a supplemental end-of-term charge.
Material Changes vs. Prior Period
- Significant Reduction in Net Loss: Net loss decreased by approximately 65% (from $9.9 million to $3.5 million) compared to Q1 2025. This improvement was driven by substantial reductions in operating expenses.
- Expense Reductions:
- R&D Expenses: Decreased by $5.0 million (67.5%), primarily due to lower personnel costs, drug manufacturing costs, and external clinical development costs.
- G&A Expenses: Decreased by $1.9 million (62.1%), driven by reduced personnel and legal costs.
- Debt Repayment (Subsequent Event): On April 1, 2026, the company repaid the outstanding $15.0 million borrowings under the Hercules Credit Facility and terminated all commitments, effectively eliminating this debt obligation immediately following the reporting period.
- Stock-Based Compensation: Total stock-based compensation was a benefit of $(987,554) in Q1 2026 compared to an expense of $2.2 million in Q1 2025, largely due to the expiration of certain cash-settled awards.
Guidance, Outlook, Risks, and Unusual Items
- Regulatory Status (Reproxalap): On March 17, 2026, the FDA issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for reproxalap. The FDA cited a "lack of substantial evidence" of efficacy and concerns regarding the reliability of study results. The company has scheduled a Type A meeting with the FDA to discuss next steps.
- AbbVie Option: As of May 7, 2026, AbbVie has not exercised its exclusive option to collaborate on reproxalap. The option period is restricted to 10 business days following FDA approval. If not exercised, Aldeyra remains solely responsible for funding further development and commercialization.
- Liquidity Outlook: Management believes cash and cash equivalents ($65.0 million) are sufficient to fund projected operating expenses and debt obligations into the second half of 2028, excluding potential licensing revenue. However, the company will likely need to secure additional funding in the future.
- Legal Proceedings: A putative securities class action lawsuit was filed on March 30, 2026, alleging violations of securities laws regarding statements about the reproxalap NDA. The company disputes the claims and intends to defend vigorously.
- Unusual Items: The company ceased development of the Helio Product Candidate (ADX-2191 for proliferative vitreoretinopathy) in 2024. Additionally, the company repaid its entire Hercules debt facility on April 1, 2026, a significant event occurring just after the quarter-end.
Investor Verification Checklist
- FDA Next Steps: Verify the outcome of the scheduled Type A meeting with the FDA regarding the reproxalap CRL and the feasibility of any required additional clinical trials.
- AbbVie Option Status: Monitor for any announcement regarding the exercise or expiration of the AbbVie option, which is critical for funding commercialization.
- Capital Requirements: Assess the company's burn rate and the timeline for potential additional equity or debt financing given the regulatory setback.
- Legal Exposure: Track the progress of the securities class action lawsuit filed in March 2026 and potential settlement or defense costs.
- Debt Status: Confirm the full repayment of the Hercules Credit Facility and the absence of any remaining covenants or obligations.